T. Ruf

No Evidence of QT Prolongation With Supratherapeutic Doses of Aleglitazar

D. Bentley, P. Jordan, S. Sturm, 2012, Journal of cardiovascular pharmacology.

Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

K. Bogman, P. N. Morcos, Carolina Sturm-Pellanda, 2017, Cancer Chemotherapy and Pharmacology.

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

A. Shaw, S. Ou, T. Mok, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin

B. Voith, H. Adelmann, W. Mück, 2000 .

OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses

S. Novello, R. Dziadziuszko, J. Mazières, 2019, Journal of Thoracic Oncology.

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib

R. Dziadziuszko, D. Planchard, E. Guerini, 2022, ESMO open.

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

R. Dziadziuszko, J. Mazières, K. Trunzer, 2022, ESMO open.

Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.

C. Funk, M. Seiberling, S. Sturm, 2012, Clinical therapeutics.

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.

A. Shaw, S. Ou, T. Mok, 2020 .